Pliant Therapeutics, Inc. (PLRX)
Automate Your Wheel Strategy on PLRX
With Tiblio's Option Bot, you can configure your own wheel strategy including PLRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PLRX
- Rev/Share 0.0
- Book/Share 4.2005
- PB 0.3262
- Debt/Equity 0.234
- CurrentRatio 11.034
- ROIC -0.7402
- MktCap 84099231.0
- FreeCF/Share -2.8864
- PFCF -0.4759
- PE -0.3821
- Debt/Assets 0.1745
- DivYield 0
- ROE -0.6756
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | PLRX | Needham | Buy | Hold | -- | -- | March 4, 2025 |
| Resumed | PLRX | Cantor Fitzgerald | -- | Neutral | -- | -- | March 4, 2025 |
| Downgrade | PLRX | Leerink Partners | Outperform | Market Perform | -- | -- | March 3, 2025 |
| Downgrade | PLRX | Stifel | Buy | Hold | -- | -- | March 3, 2025 |
| Downgrade | PLRX | Citigroup | Buy | Neutral | $40 | $4 | Feb. 10, 2025 |
| Downgrade | PLRX | Wells Fargo | Overweight | Equal Weight | $41 | $4 | Feb. 10, 2025 |
| Downgrade | PLRX | H.C. Wainwright | Buy | Neutral | -- | -- | Feb. 10, 2025 |
| Downgrade | PLRX | RBC Capital Mkts | Outperform | Sector Perform | $45 | $4 | Feb. 10, 2025 |
| Downgrade | PLRX | JP Morgan | Overweight | Neutral | -- | -- | Feb. 10, 2025 |
| Downgrade | PLRX | Canaccord Genuity | Buy | Hold | $43 | $4 | Feb. 10, 2025 |
News
Pliant Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - PLRX
Published: February 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pliant Therapeutics, Inc. ("Pliant Therapeutics, Inc.") (NASDAQ:PLRX) concerning possible violations of federal securities laws. On February 7, 2025, Pliant announced that following a prespecified data review and recommendations by the trial's independent Data Safety Monitoring Board, it had voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
Published: February 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc ("Pliant" or the "Company") (NASDAQ:PLRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Pliant Therapeutics Announces Next Steps Following DSMB Recommendation on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that, per the charter of the trial's independent Data Safety Monitoring Board (DSMB), the Company has initiated the assembly of an outside expert panel to review unblinded data from the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis (IPF).
Read More
Shareholder Rights Advocates at Levi & Korsinsky Investigate Pliant Therapeutics, Inc. (PLRX) Regarding Possible Securities Fraud Violations
Published: February 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pliant Therapeutics, Inc. ("Pliant Therapeutics, Inc.") (NASDAQ:PLRX) concerning possible violations of federal securities laws. On February 7, 2025, Pliant announced that following a prespecified data review and recommendations by the trial's independent Data Safety Monitoring Board, it had voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis.
Read More
Pliant Therapeutics, Inc. Company Investigated by the Portnoy Law Firm
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Investors can contact the law firm at no cost to learn more about recovering their losses
Read More
Lost Money on Pliant Therapeutics, Inc. (PLRX)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
Published: February 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pliant Therapeutics, Inc. ("Pliant Therapeutics, Inc.") (NASDAQ:PLRX) concerning possible violations of federal securities laws. On February 7, 2025, Pliant announced that following a prespecified data review and recommendations by the trial's independent Data Safety Monitoring Board, it had voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis.
Read More
Pliant Therapeutics, Inc. (PLRX) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
Published: February 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pliant Therapeutics, Inc. ("Pliant Therapeutics, Inc.") (NASDAQ:PLRX) concerning possible violations of federal securities laws. On February 7, 2025, Pliant announced that following a prespecified data review and recommendations by the trial's independent Data Safety Monitoring Board, it had voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis.
Read More
PLRX STOCK ALERT: Levi & Korsinsky Notifies Pliant Therapeutics, Inc. Investors of an Ongoing Investigation
Published: February 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pliant Therapeutics, Inc. ("Pliant Therapeutics, Inc.") (NASDAQ:PLRX) concerning possible violations of federal securities laws. On February 7, 2025, Pliant announced that following a prespecified data review and recommendations by the trial's independent Data Safety Monitoring Board, it had voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis.
Read More
Pliant Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - PLRX
Published: February 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pliant Therapeutics, Inc. ("Pliant Therapeutics, Inc.") (NASDAQ:PLRX) concerning possible violations of federal securities laws. On February 7, 2025, Pliant announced that following a prespecified data review and recommendations by the trial's independent Data Safety Monitoring Board, it had voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis.
Read More
Shareholder Rights Advocates at Levi & Korsinsky Investigate Pliant Therapeutics, Inc. (PLRX) Regarding Possible Securities Fraud Violations
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pliant Therapeutics, Inc. ("Pliant Therapeutics, Inc.") (NASDAQ:PLRX) concerning possible violations of federal securities laws. On February 7, 2025, Pliant announced that following a prespecified data review and recommendations by the trial's independent Data Safety Monitoring Board, it had voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis.
Read More
Investors who Lost Money on Pliant Therapeutics, Inc. Should Contact Levi & Korsinsky about an Ongoing Investigation - PLRX
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pliant Therapeutics, Inc. ("Pliant Therapeutics, Inc.") (NASDAQ:PLRX) concerning possible violations of federal securities laws. On February 7, 2025, Pliant announced that following a prespecified data review and recommendations by the trial's independent Data Safety Monitoring Board, it had voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis.
Read More
Shareholder Rights Advocates at Levi & Korsinsky Investigate Pliant Therapeutics, Inc. (PLRX) Regarding Possible Securities Fraud Violations
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pliant Therapeutics, Inc. ("Pliant Therapeutics, Inc.") (NASDAQ:PLRX) concerning possible violations of federal securities laws. On February 7, 2025, Pliant announced that following a prespecified data review and recommendations by the trial's independent Data Safety Monitoring Board, it had voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis.
Read More
About Pliant Therapeutics, Inc. (PLRX)
- IPO Date 2020-06-03
- Website https://pliantrx.com
- Industry Biotechnology
- CEO Dr. Bernard Coulie M.B.A., M.D., Ph.D.
- Employees 171